Radius Health Inc. (RDUS) Price Target Increased to $71.00 by Analysts at HC Wainwright
Radius Health Inc. (NASDAQ:RDUS) had its price target boosted by stock analysts at HC Wainwright from $55.00 to $71.00 in a research note issued on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 25.15% from the company’s previous close.
Several other research analysts also recently weighed in on RDUS. Canaccord Genuity set a $85.00 price target on shares of Radius Health and gave the stock a “buy” rating in a research report on Monday. JPMorgan Chase & Co. restated a “buy” rating and set a $70.00 price target on shares of Radius Health in a research report on Friday, August 5th. Cowen and Company restated a “buy” rating on shares of Radius Health in a research report on Thursday, August 4th. Zacks Investment Research upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Tuesday, July 5th. Finally, Jefferies Group restated a “hold” rating and set a $46.00 price target on shares of Radius Health in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $63.51.
Radius Health (NASDAQ:RDUS) opened at 56.73 on Wednesday. The company’s market cap is $2.44 billion. Radius Health has a one year low of $24.75 and a one year high of $77.10. The company has a 50 day moving average of $54.72 and a 200-day moving average of $40.96.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/radius-health-inc-rdus-price-target-increased-to-71-00-by-analysts-at-hc-wainwright.html
Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by $0.06. During the same period last year, the firm earned ($0.61) EPS. On average, equities analysts expect that Radius Health will post ($3.95) earnings per share for the current fiscal year.
Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of Radius Health by 27.9% in the second quarter. BlackRock Inc. now owns 2,852 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 623 shares in the last quarter. Fifth Third Bancorp increased its stake in shares of Radius Health by 6.2% in the second quarter. Fifth Third Bancorp now owns 3,421 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 201 shares in the last quarter. Opera Trading Capital purchased a new stake in shares of Radius Health during the first quarter worth about $138,000. Teacher Retirement System of Texas increased its stake in shares of Radius Health by 21.4% in the second quarter. Teacher Retirement System of Texas now owns 4,169 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 736 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its stake in shares of Radius Health by 11.7% in the first quarter. Envestnet Asset Management Inc. now owns 5,100 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 535 shares in the last quarter. Institutional investors and hedge funds own 99.91% of the company’s stock.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.